Anna Lawless, Radiation Oncologist, Complex Radiation Oncology Fellow at MD Anderson Cancer Center shared a post on LinkedIn:
“Very much enjoyed the opportunity to present our work on the combination of palliative radiotherapy with lenvatinib and pembrolizumab for patients with BRAF wild-type anaplastic thyroid cancer at American Society of Clinical Oncology (ASCO) ASM this year.
A special thank you to Sarah Hamidi for her mentorship and support, and to the incredible multidisciplinary team at UT MD Anderson whose expertise made this work possible.”
Other articles about Radiotherapy on OncoDaily.